Since the Supreme Court overturned Roe vs. Wade two years ago, the battle over abortion rights has oscillated between efforts to limit and enhance access across the United States. This evolving controversy is now advancing into a new domain: local pharmacies. The Supreme Court is set to examine the legality of Mifepristone, a key abortion drug, this month. Used together with Misoprostol, Mifepristone can end a pregnancy within the first 10 weeks. In anticipation, major pharmacy chains CVS and Walgreens have begun offering Mifepristone, following an FDA rule change that allows retail pharmacies to distribute the medication. Previously, obtaining these drugs was more restricted, requiring pickup from medical providers or specialized pharmacies.
This move could make access easier in states where abortion is legal, especially given CVS’s vast network of over 9,000 locations and Walgreens’ substantial presence. Yet, the long-term impact remains uncertain. Advocates for abortion rights welcome the change, but some caution that the benefits might be temporary and geographically limited. Initially, availability will be confined to certain states, with Walgreens serving New York, Pennsylvania, Massachusetts, California, and Illinois, and CVS starting in Massachusetts and Rhode Island, planning to extend to more states where legally permissible. Both chains have ruled out mail-order options for these drugs.
The Supreme Court’s upcoming decision on challenges to both the FDA’s original approval of Mifepristone over two decades ago and the recent easing of distribution rules casts a shadow over future access. These legal confrontations, initiated by anti-abortion doctors, scrutinize the FDA’s actions on various fronts. With a ruling expected by June, the availability of Mifepristone at retail pharmacies is in jeopardy, even as President Biden encourages pharmacies to get certified to dispense the drug.
